<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00940069</url>
  </required_header>
  <id_info>
    <org_study_id>LYN-LC-001</org_study_id>
    <nct_id>NCT00940069</nct_id>
  </id_info>
  <brief_title>TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer</brief_title>
  <acronym>TPEIAL</acronym>
  <official_title>A Multicenter, Open Clinical Trial of Using TS Gene Polymorphism to Predict Effect in Patients of Advanced Lung Adenocarcinoma to Pemetrexed Combining With Cisplatin Regiment as First-line Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed a multicenter, open trial of using TS gene polymorphism to
      predict advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin regiment as
      first-line treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Main eligibility criteria were histologic or cytologic proof of advanced non-small-cell
           lung cancer (NSCLC) primary treatment, normal organ function, and Eastern Cooperative
           Oncology Group performance status 0 to 2.

        2. All Patients were delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 for not less
           than 4 cycle, administered intravenously every 3 weeks. Response assessment was
           performed every 6 weeks; toxicity assessment was performed every 3 weeks.

        3. Primary end point was time to progression (TTP); secondary end points were objective
           response rate (ORR), overall survival (OS), and toxicity.

        4. The study was designed to evaluate TS(thymidylate synthase) gene polymorphism as a
           predictor for advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin
           regiment as first-line treatment.

        5. Polymorphisms of thymidylate synthase were investigated in peripheral WBC（white blood
           cell）of all patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progress</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>TS high expression genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS high expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TS low expression genotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TS low expression genotype delivered to pemetrexed 500 mg/m2 and cisplatin 75 mg/m2,for not less than 4 cycle, administered intravenously every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed</intervention_name>
    <description>'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.</description>
    <arm_group_label>TS high expression genotype</arm_group_label>
    <arm_group_label>TS low expression genotype</arm_group_label>
    <other_name>Alimta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologic or cytologic proof of advanced lung adenocarcinoma

          -  primary treatment

          -  normal organ function

          -  Eastern Cooperative Oncology Group performance status 0 to 2

        Exclusion Criteria:

          -  Symptomatic patients with brain metastases

          -  Major organ dysfunction and severe heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Luo, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Hunan Province Tumor Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nong Yang, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Province Tumor Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HuNan province tumor hospital</name>
      <address>
        <city>ChangSha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Krawczyk P, Kucharczyk T, Kowalski DM, Powrózek T, Ramlau R, Kalinka-Warzocha E, Winiarczyk K, Knetki-Wróblewska M, Wojas-Krawczyk K, Kałakucka K, Dyszkiewicz W, Krzakowski M, Milanowski J. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients. J Cancer Res Clin Oncol. 2014 Dec;140(12):2047-57. doi: 10.1007/s00432-014-1756-6. Epub 2014 Jul 16.</citation>
    <PMID>25028118</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Wang Y, Wang Y, Cheng J, Wang Y, Ha M. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC. J Biomed Sci. 2013 Jan 25;20:5. doi: 10.1186/1423-0127-20-5.</citation>
    <PMID>23350714</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>February 19, 2016</last_update_submitted>
  <last_update_submitted_qc>February 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yi Luo</investigator_full_name>
    <investigator_title>director</investigator_title>
  </responsible_party>
  <keyword>TS</keyword>
  <keyword>polymorphism</keyword>
  <keyword>lung cancer</keyword>
  <keyword>adenocarcinoma</keyword>
  <keyword>pemetrexed</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

